CHALLENGE STOCK VALIDATION

挑战库存验证

• 批准号: 8357706
• 负责人: Jean L. Patterson
• 金额: $ 3.27万
• 依托单位: TEXAS BIOMEDICAL RESEARCH INSTITUTE
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-05-01 至 2012-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8357706
• 关键词: Adenovirus Vector; Adenoviruses; Animals; Blood; Development; Drug Formulations; Enzyme-Linked Immunosorbent Assay; Filovirus; Funding; Future; Grant; Immune response; Infection; National Center for Research Resources; Primates; Principal Investigator; Research; Research Infrastructure; Resources; Serum; Source; Splenocyte; United States National Institutes of Health; Vaccination; Vaccines; Venipunctures; base; cost; enzyme linked immunospot assay; tool

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. Primary support for the subproject and the subproject's principal investigator may have been provided by other sources, including other NIH sources. The Total Cost listed for the subproject likely represents the estimated amount of Center infrastructure utilized by the subproject, not direct funding provided by the NCRR grant to the subproject or subproject staff. To date, no commercial vaccine is available to protect against infection with filoviruses. The overall aim of our project is to develop immunological tools to evaluate immune response to vaccine formulations. Two weeks prior to vaccination, blood will be collected to establish an immunological baseline. On day of vaccination, animals will be immunized with one of 5 adenovirus based vaccines or an empty adenovector control. At week 2, 3, 4, 5, 7, 9, 11, 13 post vaccination, blood will be collected via femoral venipuncture for ELISA and ELISPOT development. In addition, at week 13, animals will be euthanized for isolation of splenocytes and storage of serum for future analysis.

这个子项目是许多利用资源的研究子项目之一 由NIH/NCRR资助的中心拨款提供。子项目的主要支持 而子项目的主要调查员可能是由其他来源提供的， 包括其它NIH来源。 列出的子项目总成本可能 代表子项目使用的中心基础设施的估计数量， 而不是由NCRR赠款提供给子项目或子项目工作人员的直接资金。 迄今为止，没有商业疫苗可用于保护免受丝状病毒感染。我们项目的总体目标是开发免疫学工具，以评估疫苗制剂的免疫反应。接种前两周，将采集血液以建立免疫学基线。在接种当天，将用5种基于腺病毒的疫苗之一或空腺病毒载体对照免疫动物。 在疫苗接种后第2、3、4、5、7、9、11、13周，将通过股静脉穿刺采集血液用于ELISA和ELISPOT开发。 此外，在第13周，将对动物实施安乐死，以分离脾细胞并储存血清用于未来分析。